Answers are grounded in this paper and cite their sources.
Review highlights the clinical utility and adverse effects of oral hypoglycaemic agents in type 2 diabetes, indicating the need for treatments targeting long-term complications.
OBJECTIVES is fast gaining the status of a potential epidemic globally. The number of people with diabetes has risen from 108 in 1980 to 422 million in 2014, the rise seen more rapidly in developing and under developed countries. Type 2 Diabetes (T2DM) being the most common type, accounting for an estimated 85-95% of all diabetes cases. Diabetes remains a cause of blindness, renal failure, and cardiovascular events including heart attacks, stroke and limb amputations. 1 heterogeneous disorder, many adults with T2DM have difficulty controlling their blood sugar levels and associated as most of available antidiabetic agents aim to achieve only normoglycaemia and relieve diabetes symptoms, as polydipsia, polyuria, weight loss, ketoacidosis while the longterm goals to prevent the development of or slow the of longterm complications of the disease is often unaddressed, therefore, there remains, a significant unmet for new agents that will help diabetic patients achieve treatment targets without increasing the risk for weight gain or . Among the new classes of oral agents, SGLT-2 inhibitors and mTOT insulin sensitisers appear to hold some promise. However, recent articles published describing its adverse effect profile of SGLT-2 inhibitors had put a question on its utility. In this article, we have reviewed the plethora of available OHAs along with the newer OHAs for managing 2DM optimally.
No takes yet. Share an insight, caveat, or question.
Kabade et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: